Free Trial
→ Here’s Why Trump Won’t End The Iran War (From Banyan Hill Publishing) (Ad)tc pixel
NASDAQ:KPRX

Kiora Pharmaceuticals Q3 2026 Earnings Date & Estimates

Kiora Pharmaceuticals logo
$2.46 -0.01 (-0.40%)
As of 12:45 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Kiora Pharmaceuticals is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. The conference call is scheduled for 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Kiora Pharmaceuticals in Q3 2026

Kiora Pharmaceuticals is expected to post earnings of -$0.38 per share. In the same quarter a year earlier Kiora Pharmaceuticals reported $0.01 per share. Kiora Pharmaceuticals last reported on August 7, 2026, posting -$0.34 per share and beating the -$0.47 consensus estimate. Kiora Pharmaceuticals has beaten the consensus EPS estimate in 5 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.38
Prior-Year EPS
$0.01
Expected EPS Growth
-3,900.0%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.34 (Beat by +$0.13)
EPS Beat Rate
5 of last 8 quarters

Prepare for the Q3 2026 Call

Kiora Pharmaceuticals Q3 2026 Earnings FAQ

Kiora Pharmaceuticals (NASDAQ:KPRX) is estimated to report Q3 2026 earnings on Friday, November 6, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Kiora Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Friday, November 6, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Kiora Pharmaceuticals to post earnings of -$0.38 per share for Q3 2026.

Kiora Pharmaceuticals Earnings Headlines

Contrasting Jaguar Animal Health (NASDAQ:JAGX) & Kiora Pharmaceuticals (NASDAQ:KPRX)
October 7, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31095273
Kiora Pharmaceuticals (NASDAQ:KPRX) Shares Down 1.2% - Time to Sell?
October 6, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31090043
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 14 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Kiora Pharmaceuticals Appoints Keith J. Lane as Executive Vice President of Global Clinical Development and Regulatory Affairs
September 8, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/kiora-pharmaceuticals-appoints-keith-j-110000789.html
Analysts Have Conflicting Sentiments on These Healthcare Companies: Joint (JYNT) and Kiora Pharmaceuticals (KPRX)
August 9, 2026  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/markets-news/Tipranks/3745430/analysts-have-conflicting-sentiments-on-these-healthcare-companies-joint-jynt-and-kiora-pharmaceuticals-kprx/
Kiora Pharmaceuticals Shareholders Approve Expanded Equity Incentive Plan
June 11, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/kiora-pharmaceuticals-shareholders-approve-expanded-equity-incentive-plan?utm_source=marketbeat.com&utm_medium=referral
See More Kiora Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Kiora Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Kiora Pharmaceuticals and other key companies, straight to your email.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals (NASDAQ:KPRX) is a clinical-stage biotechnology company focused on developing treatments for diseases of the eye. Its research programs address conditions affecting the retina and other ocular tissues, with an emphasis on therapies that may offer new treatment options for patients with limited or no approved alternatives.

The company’s pipeline has included KIO-301, an investigational small-molecule photoswitch designed to provide light sensitivity and potentially restore visual function in people with inherited retinal diseases such as retinitis pigmentosa. Kiora has also developed investigational ophthalmic therapies for inflammatory and surface-related eye disorders, including KIO-104 for noninfectious uveitis and KIO-101 for dry eye disease. These candidates remain subject to clinical and regulatory evaluation.

Kiora was formerly known as EyeGate Pharmaceuticals and adopted the Kiora Pharmaceuticals name as it expanded its focus on retinal and other ophthalmic diseases. The company is headquartered in the United States and has conducted clinical development activities in the United States and internationally, including Australia. Kiora Pharmaceuticals trades on the Nasdaq under the symbol KPRX.

View Kiora Pharmaceuticals Profile
Earnings Tools